Penwest and Otsuka in third drug delivery tie-up
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical has again tapped Penwest Pharmaceuticals to develop a controlled-release formulation of one of its products. Penwest will apply its TIMERx oral delivery technology to an unidentified compound from the Japanese firm, in return for undisclosed fees and payments. The TIMERx system is based on a hydrophilic polysaccharide matrix which can be engineered to provide varying release rates. It is the third such collaboration between the two companies.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.